AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Immuron Limited has issued 877,440 new ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The issuance could impact the company's financial structure and investor relations by increasing the number of shares available in the market. Immuron operates in the biotechnology industry, developing and commercializing oral immunotherapeutic products for gut-mediated diseases. The company is listed on the Australian Securities Exchange and NASDAQ.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet